Professor Huang Jinhai's team at the School of Life Sciences of Tianjin University announced that they have successfully developed a new oral vaccine for coronavirus, according to local news media TJYun.
The vaccine uses food-grade safe Saccharomyces cerevisiae as a carrier and a new coronavirus S protein as a target to generate antibodies, reports said.
It is reported that Professor Huang Jinhai has already taken 4 times the oral coronavirus vaccine sample without any side effects. At present, the research team is seeking partners, hoping to promote the vaccine to clinical soon, and play a role in the prevention and control of the epidemic.
The team also said that the vaccine was only successfully developed, and it was a long time from market launch, without clinical validation and promotion.
Golden Sea introduced that a similar animal vaccine had been made before and it proved to be effective, so it was concluded that the vaccine developed this time might be effective. However, how the final effect can be proved through subsequent animal experiments and human experiments, I hope that qualified enterprises and units can cooperate with them to carry out follow-up work.
Why can vaccine development be completed in such a short time?
Professor Huang said that over the years, the team has built and improved a vaccine and biocontrol agent development platform using food-grade safe Saccharomyces cerevisiae as a chassis cell.
This formed a series of stable expression vectors for surface display, secretion, etc., constructed different host chassis suitable for vaccine expression and its evaluation and detection system, and formed a systematic core technology for the creation of new oral vaccines and its competitive advantages.
The mature research and development platform have greatly shortened the acquisition cycle of the new coronavirus yeast vaccine strain.
Special Report: Fighting The New Coronavirus
